St. Louis Trust Co Grows Position in Merck & Co., Inc. (NYSE:MRK)

St. Louis Trust Co increased its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 9.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,488 shares of the company’s stock after acquiring an additional 1,350 shares during the quarter. St. Louis Trust Co’s holdings in Merck & Co., Inc. were worth $2,044,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in MRK. Vermillion & White Wealth Management Group LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at about $27,000. Bare Financial Services Inc purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $28,000. Burkett Financial Services LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $30,000. Finally, RIA Advisory Group LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at approximately $30,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MRK shares. Berenberg Bank increased their price objective on shares of Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Merck & Co., Inc. in a research report on Tuesday, June 18th. Wells Fargo & Company increased their price target on shares of Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 27th. Truist Financial increased their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a report on Friday, April 26th. Finally, Societe Generale downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price target on the stock. in a report on Monday, March 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $133.00.

Get Our Latest Research Report on Merck & Co., Inc.

Merck & Co., Inc. Trading Down 0.5 %

Shares of MRK stock opened at $125.76 on Tuesday. The stock’s fifty day moving average is $129.05 and its two-hundred day moving average is $125.26. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The firm has a market capitalization of $318.53 billion, a P/E ratio of 139.73, a PEG ratio of 2.44 and a beta of 0.38. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $134.63.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The business had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.40 EPS. Research analysts expect that Merck & Co., Inc. will post 8.62 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, July 8th. Investors of record on Monday, June 17th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 2.45%. The ex-dividend date was Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 342.22%.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Read More

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.